Lyrette: Renewing Continence Objective and Subjective Efficacy Study

Inclusion Criteria: * Age 35 to 60 years * Female gender * Ability to complete all study requirements * Body Mass Index ≤ 35 * Incontinence Quality of Life score (IQOL) ≥ 55 * Leak Point Pressure (LPP) ≥ 90 cm H2O and * Maximal Urethral Closure Pressure (MUCP) ≥ 45 cm H2O * 3 to10 stress leaks recorded in the 3 day voiding diary * Clinical history of stress urinary incontinence for ≥ 12 months * Clinical diagnosis of stress urinary incontinence by study physician * Clinical diagnosis of mixed incontinence with predominant stress component. * Clinical diagnosis of bladder outlet hypermobility by a study physician * Has failed conservative therapy (Kegels, biofeedback) and/or has not received conservative therapy for a period of at least 3 months prior to enrollment in the study. * Medical Epidemiologic, and Social Aspects of Aging (MESA)stress symptom percentage score greater than urge symptom percentage score * Post-void residual ≤ 100 cc with Stage II or lower pelvic organ prolapsed * Urethral length ≥ 3 cm * Is not a current smoker * If subject has children, at least 1 year has elapsed after child birth and cessation of breastfeeding for at least 3 months, at enrollment. Exclusion Criteria: * ASA III or IV classification * Current or planned pregnancy within the next 12 months * Clinical diagnosis of detrusor overactivity by urodynamic evaluation * Clinical diagnosis of mixed urinary incontinence with predominant urge component * Clinical diagnosis of primary urge urinary incontinence * Clinical diagnosis of gravitational loss * Stage III, IV Pelvic Organ Prolapse * Less than 2 grams of urine leakage during 1 hour stress pad test * Previous surgery, RF micro-remodeling, or injection of bulking agents specifically for the treatment of urinary incontinence * Current incontinence treatment with electrical stimulation, biofeedback, and/or medications * Previous urethral and/or bladder surgery (excluding diagnostic endoscope) * Current urinary tract infection * History of chronic urinary tract infections * History of recurrent pyelonephritis * History of interstitial cystitis * History of upper or lower urinary tract neoplasm * History of upper or lower anatomic urinary tract abnormality or disorder * History of acute or chronic renal failure * Coagulopathy * Immunosuppression (pathological or medication induced) * Collagen vascular disease (scleroderma, etc.) * Presence of a pacemaker, AICD, or other electrical health maintenance device, bladder neuro-modulation device. * History of COPD or other obstructive pulmonary disease * Life expectancy \< 12 months * Knowingly will be relocating out of practice area within 12 months of initiation of the study